In addition, several experimental models recently suggested that angiotensin II could be involved in cancer development and progression [8, 9] and that RAS blockage by AT1-R antagonists or Angiotensin converting enzyme inhibitors (ACE-Is) could be useful in cancer therapy [10]. This evidence concerns the gene ACE and cancer.